Dupilumab for the Treatment of Cutaneous Immune-Related Adverse Events: A Systematic Review.

ABSTRACT: The emergence of immune checkpoint inhibitors has revolutionized the landscape of cancer treatment in the modern era. However, cutaneous immune-related adverse events (cirAEs) are common, significantly affecting patients' quality of life and often leading to treatment discontinuation, which may compromise oncological outcomes. Dupilumab, an immunoglobulin G4 (IgG4) human monoclonal antibody targeting interleukin (IL)-4 and IL-13 receptors, is widely used for dermatologic conditions but remains unapproved for cirAEs due to the limited and scattered supporting evidence. This review aimed to summarize the available evidence regarding the use of dupilumab for the management of cirAEs. A systematic review was conducted using MEDLINE/PubMed, Scopus, and Web of Science in adherence to the Preferr

SUBMITTER: Koumprentziotis IA 

PROVIDER: S-EPMC12418913 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature